Last reviewed · How we verify
AK117 in combination with AK112
AK117 and AK112 are bispecific antibodies that simultaneously engage immune checkpoint pathways to enhance anti-tumor T-cell responses.
AK117 and AK112 are bispecific antibodies that simultaneously engage immune checkpoint pathways to enhance anti-tumor T-cell responses. Used for Advanced or metastatic solid tumors (Phase 3 evaluation).
At a glance
| Generic name | AK117 in combination with AK112 |
|---|---|
| Sponsor | Akeso |
| Drug class | Bispecific monoclonal antibody |
| Target | PD-1/LAG-3 (AK117) and PD-L1/TIM-3 (AK112) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AK117 is a bispecific antibody targeting PD-1 and LAG-3, while AK112 targets PD-L1 and TIM-3. Together, they block multiple inhibitory immune checkpoints on T cells, releasing brakes on anti-tumor immunity and promoting T-cell activation and proliferation. This dual-checkpoint blockade approach aims to overcome resistance to single-agent checkpoint inhibition.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 evaluation)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Diarrhea
- Rash
Key clinical trials
- A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer (PHASE2)
- A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors (PHASE1, PHASE2)
- A Study of AK112 in Advanced Malignant Tumors (PHASE1, PHASE2)
- Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN (PHASE3)
- A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK117 in combination with AK112 CI brief — competitive landscape report
- AK117 in combination with AK112 updates RSS · CI watch RSS
- Akeso portfolio CI